Emerging evidence suggests weight regain after GLP-1 treatment may be mitigated through personalised long-term strategies

While clinical trials show significant weight regain after stopping GLP-1 medicines like semaglutide and tirzepatide, recent real-world research highlights the potential for sustained progress through follow-up care and lifestyle modifications, underscoring the importance of personalised long-term approaches.

Research on GLP-1 medicines suggests that stopping treatment often leads to some degree of weight regain, but the size of that rebound varies widely and should not be treated as a personal forecast. The most cited finding comes from semaglutide trials, where participants regained much of their earlier loss after treatment ended. But newer evidence, including real-world studies, shows that some patients maintain their progress with follow-up care, alternative treatment and lifestyle changes.

A systematic review and meta-regression indexed in PubMed, which analysed 48 studies, found that about 60% of the weight lost during treatment was regained within a year after GLP-1 receptor agonists were stopped, with regain eventually plateauing at roughly 75.3%. Even so, the researchers stressed that individual responses differ, underlining the need for personalised weight-management plans.

The semaglutide data that shaped much of the discussion came from the STEP 1 extension study. After 68 weeks of semaglutide and lifestyle support, participants had lost an average of 17.3% of their body weight. One year after both were withdrawn, they had regained an average of 11.6 percentage points, which researchers described as around two-thirds of the original loss. Another semaglutide trial, STEP 4, found that people who switched to placebo after an initial treatment period gained weight, while those who stayed on the drug kept losing.

Tirzepatide has shown a similar pattern in trial settings. In SURMOUNT-4, participants who were switched from tirzepatide to placebo gained an average of 14.0% of body weight from randomisation to week 88, while those who stayed on treatment lost a further 5.5% on average. A separate meta-analysis published in The BMJ also found that weight regain after stopping weight-loss medicines was common across a broader range of studies.

However, real-world evidence has been less uniform. Cleveland Clinic said a study of nearly 8,000 adults found that stopping semaglutide and tirzepatide did not necessarily lead to major weight regain in everyday practice, because many patients continued with other therapies or lifestyle measures. Medical News Today reported on another real-world study in which people who stopped GLP-1 drugs within three to 12 months regained only a minimal amount of weight after a year. Taken together, the findings suggest that medication is only one part of the picture.

That broader context matters because appetite, fullness and calorie intake are only part of weight regulation. Sleep, stress, other medicines, underlying health conditions, mobility, nutrition, physical activity and social support can all shape what happens after treatment changes. Anthony Colón, RN, says the key takeaway is not that GLP-1 medicines fail, but that weight management works best when patients and clinicians plan for the long term, including what will happen if treatment needs to change or stop.